Xu D, Yin S, Shu Y
NPJ Precis Oncol. 2024; 8(1):133.
PMID: 38879686
PMC: 11180135.
DOI: 10.1038/s41698-024-00627-5.
Kadariya Y, Sementino E, Shrestha U, Gorman G, White J, Ross E
Carcinogenesis. 2022; 43(12):1137-1148.
PMID: 36355620
PMC: 10122428.
DOI: 10.1093/carcin/bgac089.
Chapel D, Hornick J, Barlow J, Bueno R, Sholl L
Mod Pathol. 2022; 35(10):1383-1397.
PMID: 35459788
PMC: 9529776.
DOI: 10.1038/s41379-022-01081-z.
Sementino E, Kadariya Y, Cheung M, Menges C, Tan Y, Kukuyan A
Mol Cancer Res. 2022; 20(5):699-711.
PMID: 35082167
PMC: 9081258.
DOI: 10.1158/1541-7786.MCR-21-0837.
Hajj G, Cavarson C, Pinto C, Venturi G, Navarro J, Cordeiro de Lima V
J Bras Pneumol. 2021; 47(6):e20210129.
PMID: 34909922
PMC: 8836658.
DOI: 10.36416/1806-3756/e20210129.
YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance.
Szulzewsky F, Holland E, Vasioukhin V
Dev Biol. 2021; 475:205-221.
PMID: 33428889
PMC: 8107117.
DOI: 10.1016/j.ydbio.2020.12.018.
Somatic Epigenetic Silencing of Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
Tan Y, Sementino E, Cheung M, Peri S, Menges C, Kukuyan A
Clin Cancer Res. 2020; 27(4):1200-1213.
PMID: 33203643
PMC: 7887036.
DOI: 10.1158/1078-0432.CCR-18-3683.
Malignant mesothelioma metastatic to the oral region and latest topics (Review).
Ohnishi Y, Fujii T, Sakamoto T, Watanabe M, Motohashi T, Kubo H
Mol Clin Oncol. 2020; 13(5):61.
PMID: 32963780
PMC: 7490794.
DOI: 10.3892/mco.2020.2131.
Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.
Abbott D, Bortolotto C, Benvenuti S, Lancia A, Filippi A, Stella G
Cancers (Basel). 2020; 12(5).
PMID: 32392897
PMC: 7281319.
DOI: 10.3390/cancers12051186.
Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Iwasaki A, Nabeshima K
Mod Pathol. 2019; 33(2):235-244.
PMID: 31231129
DOI: 10.1038/s41379-019-0309-6.
Inactivation of Cooperates with Losses of and to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
Kukuyan A, Sementino E, Kadariya Y, Menges C, Cheung M, Tan Y
Cancer Res. 2019; 79(16):4113-4123.
PMID: 31151962
PMC: 6697648.
DOI: 10.1158/0008-5472.CAN-18-4093.
MicroRNA-146b-3p Promotes Cell Metastasis by Directly Targeting in Human Papillary Thyroid Cancer.
Yu C, Zhang L, Luo D, Yan F, Liu J, Shao S
Thyroid. 2018; 28(12):1627-1641.
PMID: 30244634
PMC: 6308293.
DOI: 10.1089/thy.2017.0626.
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers (Basel). 2018; 10(4).
PMID: 29565815
PMC: 5923345.
DOI: 10.3390/cancers10040090.
Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.
Tan Y, Sementino E, Chernoff J, Testa J
Am J Cancer Res. 2017; 7(8):1724-1737.
PMID: 28861328
PMC: 5574944.
Novel insights into mesothelioma biology and implications for therapy.
Yap T, Aerts J, Popat S, Fennell D
Nat Rev Cancer. 2017; 17(8):475-488.
PMID: 28740119
DOI: 10.1038/nrc.2017.42.
An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova D, Semenova G, Kuo Y, Andrews A, Ammoun S, Hanemann C
Cancer Res. 2017; 77(18):5026-5038.
PMID: 28729415
PMC: 5600854.
DOI: 10.1158/0008-5472.CAN-16-2834.
Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells.
Blum W, Pecze L, Felley-Bosco E, Wu L, de Perrot M, Schwaller B
Stem Cell Reports. 2017; 8(4):1005-1017.
PMID: 28285878
PMC: 5390099.
DOI: 10.1016/j.stemcr.2017.02.005.
Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
Ruggieri M, Pratico A, Serra A, Maiolino L, Cocuzza S, di Mauro P
Acta Otorhinolaryngol Ital. 2016; 36(5):345-367.
PMID: 27958595
PMC: 5225790.
DOI: 10.14639/0392-100X-1093.
FAK and paxillin, two potential targets in pancreatic cancer.
Kanteti R, Batra S, Lennon F, Salgia R
Oncotarget. 2016; 7(21):31586-601.
PMID: 26980710
PMC: 5058780.
DOI: 10.18632/oncotarget.8040.
Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.
Morrow K, Das S, Meng E, Menezes M, Bailey S, Metge B
Oncotarget. 2016; 7(14):17991-8005.
PMID: 26908451
PMC: 4951266.
DOI: 10.18632/oncotarget.7494.